Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon β-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.
|Number of pages||3|
|Journal||Journal of Neuropsychiatry and Clinical Neurosciences|
|Publication status||Published - Jun 2004|
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology